CIK 0001831828 · Large accelerated filer
Vera Therapeutics, Inc.
Sign in to watch- Ticker
- VERA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812744449
- Phone
- 650-770-0077
- Business address
- 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE, CA, 94005
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,334,142
- in 2 filings, $1.3M under 10b5-1 plans
Net −$1,334,142. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 98 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-14 | Fordyce Marshall PRESIDENT AND CEO | Sale 10b5-1 | −14,130 | $43.66 | $617K | 244,065 |
| 2026-04-14 | Fordyce Marshall PRESIDENT AND CEO | Sale 10b5-1 | −7,921 | $44.58 | $353K | 236,144 |
| 2026-04-14 | Fordyce Marshall PRESIDENT AND CEO | Sale 10b5-1 | −900 | $45.51 | $41K | 235,244 |
| 2026-03-23 | Wright-Mitchell Jane Chief Legal Officer | Grant or award | +42,403 | 42,403 | ||
| 2026-03-23 | Wright-Mitchell Jane Chief Legal Officer | Grant or award · Stock Option (right to buy) | +56,850 | 56,850 | ||
| 2026-03-13 | Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR | Option exercise | +10,000 | $3.94 | $39K | 75,754 |
| 2026-03-13 | Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR | Option exercise · Stock Option (right to buy) | −10,000 | 38,589 | ||
| 2026-03-05 | Hite Christopher Director | Grant or award · Stock Option (right to buy) | +24,937 | 24,937 | ||
| 2026-02-23 | Skelton Laurence Matthew Chief Commercial Officer | Sale | −1,582 | $41.98 | $66K | 64,218 |
| 2026-02-23 | Brenner Robert Chief Medical Officer | Sale | −2,151 | $41.98 | $90K | 50,947 |
| 2026-02-23 | Grant Sean CHIEF FINANCIAL OFFICER | Sale | −4,949 | $41.98 | $208K | 114,181 |
| 2026-02-23 | Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR | Sale | −3,117 | $41.98 | $131K | 64,722 |
| 2026-02-23 | Fordyce Marshall PRESIDENT AND CEO | Sale | −16,925 | $41.98 | $711K | 257,163 |
| 2026-02-23 | Turner William D. Chief Regulatory Officer | Sale | −2,187 | $41.98 | $92K | 45,313 |
| 2026-02-23 | JOHNSON DAVID LEE Chief Operating Officer | Sale | −2,579 | $41.98 | $108K | 45,727 |
| 2026-02-04 | Skelton Laurence Matthew Chief Commercial Officer | Grant or award | +20,000 | 65,800 | ||
| 2026-02-04 | Skelton Laurence Matthew Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2026-02-04 | Brenner Robert Chief Medical Officer | Grant or award | +25,000 | 53,098 | ||
| 2026-02-04 | Brenner Robert Chief Medical Officer | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2026-02-04 | Grant Sean CHIEF FINANCIAL OFFICER | Grant or award | +25,000 | 119,130 |
Page 3 of 17 · 321 trades